Abstract
Renal cell carcinoma (RCC) represents approximately 15%, presenting as advanced or metastatic, where surgery is not curative. The prognosis of patients with advanced or metastatic CRC can vary from a few months to a few years, depending on the clinical, pathological and radiological characteristics of the disease. Currently, anti-monoclonals are being used, which is based on immunotherapy-based as checkpoint inhibitors in the initial systemic therapy of advanced treatment of clear cell RCC. This research presents a clinical case where immunotherapy plays a role through the use of anti-monoclonals for the approach of a male patient with metastatic kidney disease who presents a clinical response after surgical treatment and immunotherapy for two years without evidence of oncological disease to date.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
